The newly developed BMI1 inhibitor PTC209 has efficacy in colon and lung cancer by targeting cancer stem cells30 and has been shown to inhibit prostate cancer stem cell tumor growth, which is usually AR negative27. This evidence concerns the gene AR and neoplasm.